Results 271 to 280 of about 89,659 (294)
Some of the next articles are maybe not open access.
American Journal of Cardiovascular Drugs, 2012
Dual antiplatelet therapy with acetylsalicylic acid (aspirin) and clopidogrel is a guideline-recommended standard of care for patients with acute coronary syndromes (ACS) and those who undergo percutaneous coronary intervention (PCI). Despite a large body of clinical evidence obtained from randomized clinical trials and patient registries supporting ...
Saihari Sadanandan, Inder M. Singh
openaire +2 more sources
Dual antiplatelet therapy with acetylsalicylic acid (aspirin) and clopidogrel is a guideline-recommended standard of care for patients with acute coronary syndromes (ACS) and those who undergo percutaneous coronary intervention (PCI). Despite a large body of clinical evidence obtained from randomized clinical trials and patient registries supporting ...
Saihari Sadanandan, Inder M. Singh
openaire +2 more sources
European Heart Journal, 2020
AIMS In a randomized, parallel, blinded study, we investigate the impact of clopidogrel, prasugrel, or ticagrelor on peripheral endothelial function in patients undergoing stenting for an acute coronary syndrome.
B. Schnorbus +7 more
semanticscholar +1 more source
AIMS In a randomized, parallel, blinded study, we investigate the impact of clopidogrel, prasugrel, or ticagrelor on peripheral endothelial function in patients undergoing stenting for an acute coronary syndrome.
B. Schnorbus +7 more
semanticscholar +1 more source
The Journal of Pediatrics, 2005
Abstract Background: Children with congenital heart problems have an increased incidence (up to 4%) of thrombotic vascular complications, particularly after interventional catheterization procedures that include device implantation. Clopidogrel, a thienopyridine derivative, is a specific platelet aggregation inhibitor. The preferred anti-
Yaron Finkelstein +4 more
openaire +4 more sources
Abstract Background: Children with congenital heart problems have an increased incidence (up to 4%) of thrombotic vascular complications, particularly after interventional catheterization procedures that include device implantation. Clopidogrel, a thienopyridine derivative, is a specific platelet aggregation inhibitor. The preferred anti-
Yaron Finkelstein +4 more
openaire +4 more sources
Interaction of Clopidogrel and Omeprazole
New England Journal of Medicine, 2010To the Editor: The label for clopidogrel warns physicians to “avoid concomitant use of . . . strong or moderate CYP2C19 inhibitors.” Such inhibitors (e.g., omeprazole) decrease the formation of the active metabolite of clopidogrel, the source of its antiplatelet effects.
Robert Temple, Mary Ross Southworth
openaire +2 more sources
Circulation, 2018
Background: Elderly patients are at elevated risk of both ischemic and bleeding complications after an acute coronary syndrome and display higher on-clopidogrel platelet reactivity compared with younger patients.
S. Savonitto +66 more
semanticscholar +1 more source
Background: Elderly patients are at elevated risk of both ischemic and bleeding complications after an acute coronary syndrome and display higher on-clopidogrel platelet reactivity compared with younger patients.
S. Savonitto +66 more
semanticscholar +1 more source
Smoking, atherothrombosis and clopidogrel
Heart, 2012Smoking is well understood to increase the risk of atherothrombotic events by some two to threefold.1–3 Putting it another way, in 2003 the SCORE project estimated that over a period of 10 years smokers compared with non-smokers have approximately twice the risk of a fatal cardiovascular event.4 Set against this elevation in risk, it was reported in ...
Mark J. Paul-Clark +2 more
openaire +3 more sources
Pharmacogenomics of Clopidogrel
2014In "Handbook of Pharmacogenomics and stratified medicine" (edited by Sandosh Padmanabhan of the University of Glasgow, UK), the Chapter 25 "Pharmacogenomics of clopidogrel" (by Betti Giusti, Claudia Saracini, Silvia Galora, Rossella Marcucci) addresses the state of the art for this issue.
GIUSTI, BETTI +3 more
openaire +2 more sources
The “Clopidogrel Resistance” Trap
The American Journal of Cardiology, 2007a p w b e p “ S b s “ t a s i n i v t p m d e o n s u a b o b b S f d v r p e w a a ( r d p d Q v f t o w o Numerous randomized trials have indicated the benefits f clopidogrel either as an alternative1 or as an adjunct2 to spirin for the secondary prevention of acute vascular vents, including absolute mortality reduction in the largest ver acute ...
openaire +3 more sources
Clopidogrel resistance / Clopidogrel-Resistenz
LaboratoriumsMedizin, 2006Meinrad Gawaz, Tobias Geisler
openaire +2 more sources